Perrigo Company plc (PIG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Perrigo Company plc (PIG) has a cash flow conversion efficiency ratio of 0.060x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€175.40 Million ≈ $205.06 Million USD) by net assets (€2.94 Billion ≈ $3.43 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Perrigo Company plc to measure how much of total assets are equity-financed.
Perrigo Company plc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Perrigo Company plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Perrigo Company plc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Perrigo Company plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Perrigo Company plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Jinlu Group Co Ltd
SHE:000510
|
-0.019x |
|
Luoyang Longhua Heat Trans Energy
SHE:300263
|
0.024x |
|
Ircon International Limited
NSE:IRCON
|
0.013x |
|
SonoScape Medical Corp
SHE:300633
|
-0.040x |
|
Orora Ltd
AU:ORA
|
0.082x |
|
Weibo Corp
NASDAQ:WB
|
0.055x |
|
Shenzhen Urban Transport Planning Center Co. Ltd.
SHE:301091
|
N/A |
|
Srisawad Power 1979 PCL
BK:SAWAD
|
0.025x |
Annual Cash Flow Conversion Efficiency for Perrigo Company plc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Perrigo Company plc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see PIG company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €2.94 Billion ≈ $3.43 Billion |
€238.50 Million ≈ $278.83 Million |
0.081x | -3.30% |
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
€362.90 Million ≈ $424.27 Million |
0.084x | -1.21% |
| 2023-12-31 | €4.77 Billion ≈ $5.57 Billion |
€405.50 Million ≈ $474.07 Million |
0.085x | +34.01% |
| 2022-12-31 | €4.84 Billion ≈ $5.66 Billion |
€307.30 Million ≈ $359.27 Million |
0.063x | +109.18% |
| 2021-12-31 | €5.15 Billion ≈ $6.02 Billion |
€156.30 Million ≈ $182.73 Million |
0.030x | -73.03% |
| 2020-12-31 | €5.66 Billion ≈ $6.61 Billion |
€636.20 Million ≈ $743.78 Million |
0.113x | +68.38% |
| 2019-12-31 | €5.80 Billion ≈ $6.79 Billion |
€387.80 Million ≈ $453.38 Million |
0.067x | -36.14% |
| 2018-12-31 | €5.67 Billion ≈ $6.63 Billion |
€593.00 Million ≈ $693.28 Million |
0.105x | -7.63% |
| 2017-12-31 | €6.17 Billion ≈ $7.21 Billion |
€698.90 Million ≈ $817.09 Million |
0.113x | +3.03% |
| 2016-12-31 | €5.96 Billion ≈ $6.97 Billion |
€654.90 Million ≈ $765.65 Million |
0.110x | -- |
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and ora… Read more